
Figure S1. The efficacy (HIV-1 RNA < 50 copies/mL) by FDA Snapshot analysis (ITT) at Week 48 (primary endpoint), 96 and 144.


Efficacy (HIV-1 RNA < 50 copies/mL) by FDA Snapshot analysis (ITT) at Week 48 (primary endpoint), 96 and 144



Footnote: *Virologic failure includes 3 categories: 1) HIV-1 RNA \geq 50 copies/mL; 2) study drug discontinuation due to lack of efficacy; 3) study drug discontinuation due to other reasons (investigator's discretion, withdrew consent, lost to follow-up, subject noncompliance, protocol violation, pregnancy) and last available HIV-1 RNA \geq 50 copies/mL

Figure S2. The efficacy (HIV-1 RNA < 50 copies/mL) by FDA Snapshot analysis (ITT) at Week 144 by pre-specified subgroups.

Efficacy (HIV-1 RNA < 50 copies/mL) by FDA Snapshot analysis (ITT) at Week 144 by pre-specified subgroups



Difference in response rate and 95% CI were calculated based on the Mantel-Haenszel proportions adjusted by baseline HIV-1 RNA stratum.

- -30 -25 -20 -15 -10 -5 0 5 10 15 20 25 30 Differences in Percentages (95% CI)